ATE496890T1 - Pyridinderivate für die behandlung von stoffwechselstörungen, die mit insulinresistenz oder hyperglykämie in zusammenhang stehen - Google Patents

Pyridinderivate für die behandlung von stoffwechselstörungen, die mit insulinresistenz oder hyperglykämie in zusammenhang stehen

Info

Publication number
ATE496890T1
ATE496890T1 AT07826467T AT07826467T ATE496890T1 AT E496890 T1 ATE496890 T1 AT E496890T1 AT 07826467 T AT07826467 T AT 07826467T AT 07826467 T AT07826467 T AT 07826467T AT E496890 T1 ATE496890 T1 AT E496890T1
Authority
AT
Austria
Prior art keywords
hyperglycemia
treatment
insulin resistance
disorders associated
metabolic disorders
Prior art date
Application number
AT07826467T
Other languages
English (en)
Inventor
Nabajyoti Deka
Sivaramakrishnan Hariharan
Swapnil Bajare
Rosalind Marita
Original Assignee
Piramal Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Piramal Life Sciences Ltd filed Critical Piramal Life Sciences Ltd
Application granted granted Critical
Publication of ATE496890T1 publication Critical patent/ATE496890T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
AT07826467T 2006-09-21 2007-09-20 Pyridinderivate für die behandlung von stoffwechselstörungen, die mit insulinresistenz oder hyperglykämie in zusammenhang stehen ATE496890T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84619406P 2006-09-21 2006-09-21
US87567206P 2006-12-18 2006-12-18
PCT/IB2007/053811 WO2008035305A2 (en) 2006-09-21 2007-09-20 Pyridine derivatives for the treatment of metabolic disorders related to insulin resistance or hyperglycemia

Publications (1)

Publication Number Publication Date
ATE496890T1 true ATE496890T1 (de) 2011-02-15

Family

ID=39048032

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07826467T ATE496890T1 (de) 2006-09-21 2007-09-20 Pyridinderivate für die behandlung von stoffwechselstörungen, die mit insulinresistenz oder hyperglykämie in zusammenhang stehen

Country Status (19)

Country Link
US (5) US8269010B2 (de)
EP (2) EP2094687A1 (de)
JP (2) JP5331953B2 (de)
KR (2) KR20090075827A (de)
AR (2) AR062940A1 (de)
AT (1) ATE496890T1 (de)
AU (2) AU2007298540B2 (de)
BR (2) BRPI0718510A2 (de)
CA (2) CA2663901A1 (de)
DE (1) DE602007012299D1 (de)
DK (1) DK2094663T3 (de)
IL (2) IL197694A0 (de)
MX (2) MX2009002905A (de)
NZ (2) NZ576196A (de)
PL (1) PL2094663T3 (de)
PT (1) PT2094663E (de)
RU (2) RU2448093C2 (de)
TW (2) TW200817364A (de)
WO (2) WO2008035306A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2567959B1 (de) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamid-derivate als kinaseinhibitoren
WO2013117963A1 (en) 2012-02-09 2013-08-15 Piramal Enterprises Limited Stable oral tablet dosage form of an antidiabetic compound
CN105324376B (zh) 2013-06-27 2017-06-23 辉瑞大药厂 杂芳族化合物及其作为多巴胺d1配体的用途
WO2014207508A1 (en) * 2013-06-27 2014-12-31 Piramal Enterprises Limited Pyridyl compound suitable for the treatment of metabolic disorders
EA028614B1 (ru) * 2014-05-22 2017-12-29 Общество С Ограниченной Ответственностью "Русские Фармацевтические Технологии" Селективные ингибиторы, нарушающие взаимодействие рецептора фактора роста фибробластов и frs2, для профилактики и лечения рака
EP2974729A1 (de) 2014-07-17 2016-01-20 Abivax Chinolinderivate zur Verwendung bei der Behandlung von Entzündungskrankheiten
EP3669873A1 (de) 2018-12-20 2020-06-24 Abivax Chinolinderivate zur verwendung bei der behandlung von entzündlichen krankheiten

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5084085A (en) * 1986-08-20 1992-01-28 Fmc Corporation Herbicidal aryloxyphenyltriazolinones and related compounds
UA58494C2 (uk) * 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
US6583157B2 (en) * 1998-01-29 2003-06-24 Tularik Inc. Quinolinyl and benzothiazolyl modulators
AU782404B2 (en) 1999-04-28 2005-07-28 Sanofi-Aventis Deutschland Gmbh Tri-aryl acid derivatives as PPAR receptor ligands
US7041691B1 (en) * 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
EP1192137B1 (de) * 1999-06-30 2013-10-23 Amgen Inc. Verbindungen zum modulieren der ppar-gamma aktivität
AU7163701A (en) * 2000-06-28 2002-01-08 Tularik Inc Quinolinyl and benzothiazolyl ppar-gamma modulators
BRPI0411255A (pt) * 2003-06-12 2006-08-01 Novo Nordisk As composto, composição farmacêutica, uso de um composto, métodos de tratar um distúrbio de um paciente, e, processo para a preparação de um composto
US7223761B2 (en) * 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
US8188277B2 (en) * 2004-08-06 2012-05-29 Otsuka Pharmaceutical Co., Ltd. Aromatic compounds for suppressing the generation of collagen
CN101035762B (zh) * 2004-10-04 2010-09-29 霍夫曼-拉罗奇有限公司 用于糖尿病的作为11-β抑制剂的烷基(alkil)-吡啶类

Also Published As

Publication number Publication date
WO2008035305A2 (en) 2008-03-27
TW200817364A (en) 2008-04-16
CA2663943A1 (en) 2008-03-27
MX2009002906A (es) 2009-06-30
AU2007298539B2 (en) 2013-05-02
JP2010504321A (ja) 2010-02-12
KR20090075827A (ko) 2009-07-09
CA2663901A1 (en) 2008-03-27
EP2094663B1 (de) 2011-01-26
JP2010504322A (ja) 2010-02-12
BRPI0718510A2 (pt) 2013-11-19
AR062941A1 (es) 2008-12-17
DE602007012299D1 (de) 2011-03-10
US8269010B2 (en) 2012-09-18
JP5331953B2 (ja) 2013-10-30
NZ576196A (en) 2011-12-22
RU2009114544A (ru) 2010-10-27
PL2094663T3 (pl) 2011-07-29
KR20090074775A (ko) 2009-07-07
US20130040988A1 (en) 2013-02-14
DK2094663T3 (da) 2011-04-26
RU2009114545A (ru) 2010-10-27
WO2008035305A8 (en) 2009-03-12
RU2460729C2 (ru) 2012-09-10
AU2007298540B2 (en) 2013-02-21
TW200820970A (en) 2008-05-16
PT2094663E (pt) 2011-04-19
US20120309786A1 (en) 2012-12-06
US8030324B2 (en) 2011-10-04
AR062940A1 (es) 2008-12-17
US20100022554A1 (en) 2010-01-28
US20090247574A1 (en) 2009-10-01
WO2008035306A1 (en) 2008-03-27
EP2094687A1 (de) 2009-09-02
MX2009002905A (es) 2009-06-19
IL197694A0 (en) 2009-12-24
AU2007298540A1 (en) 2008-03-27
EP2094663A2 (de) 2009-09-02
US20110312970A1 (en) 2011-12-22
IL197695A0 (en) 2009-12-24
RU2448093C2 (ru) 2012-04-20
WO2008035305A3 (en) 2008-06-12
AU2007298539A1 (en) 2008-03-27
BRPI0717106A2 (pt) 2013-10-08
US8349862B2 (en) 2013-01-08
NZ576197A (en) 2011-12-22

Similar Documents

Publication Publication Date Title
ATE496890T1 (de) Pyridinderivate für die behandlung von stoffwechselstörungen, die mit insulinresistenz oder hyperglykämie in zusammenhang stehen
WO2010049678A3 (en) Treatment of energy utilization diseases
IL219529A (en) Annotated 4-aminocyclohexane history, medications containing them and the use of history to prepare pain medication
MX2009011359A (es) Derivados de pirimidinona y sus metodos de uso.
MX2010004450A (es) Derivados heterociclo biciclicos y su uso como moduladores de la actividad de gpr119.
WO2011130729A3 (en) Methods for treating metabolic disorders using fgf
FR2939356B1 (fr) Article, stratifie comprenant cet article, vetement comprenant ce stratifie, et procede de fabrication de l'article
BR112012001344A2 (pt) derivados de 17hidróxi-17-pentafluoroetil-estra-4,9(10)-dieno-11-arila, método de produção destes e uso destes para o tratamento de doenças
WO2005103002A3 (de) Neue alkin-verbindungen mit mch-antagonistischer wirkung und diese verbindungen enthaltende arzneimittel
IL202269A0 (en) Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
PL2254870T3 (pl) Pochodne 1-benzylo-3-hydroksymetyloindazolu i ich zastosowanie w leczeniu chorób opartych na ekspresji MCP-1, CX3CR1
MX2009011357A (es) Derivados de tetrahidropirido[4,3-d] pirimidinona y metodos de uso de los mismos.
IL198112A0 (en) 3-aminoimidazo [1,2-a]pyridine derivatives having an sglt1-and sglt2-inhibiting action for the treatment of type 1 and type 2 diabetes
DK2081950T3 (da) Med irinotecanbehandling forbundne ekspressionsprofiler
IL212707A0 (en) Compounds, pharmaceutical composition and methods for use in treating metabolic disorders
IL226386A0 (en) Medical treatment for metabolic syndrome, type 2 diabetes, obesity or pre-diabetes
HK1160681A1 (zh) 用於與代謝綜合征、心血管疾病和/或胰島素抗性相關的病症的診斷、預後、監測和治療追踪的體外方法
FR2922209B1 (fr) 5,6-DIARYLES PYRIDINES SUBSTITUES EN POSITION 2 et 3, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE.
BR112013030171A2 (pt) composição comestível, método para reduzir a amplitude de pico de glicose pós-prandial no sangue ou resposta glicêmica em uma pessoa não diabética, método para tratar uma pessoa com necessidade de tratamento para diabetes do tipo 2 e uso da composição
ZA201007061B (en) Pyridopyrazinones derivatives insulin secretion stimulators,methods for obtaining them and use thereof for the treatment of diabetes
EP2046313A4 (de) Verwendung von naphthochinonen bei der behandlung und kontrolle von diabetes, insulinresistenz und hyperglykämie
BRPI0811266A2 (pt) Método de acupuntura e uma agulha para realizar o mesmo.
ZA201008505B (en) Arylpyrazinone derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes
WO2012174534A3 (en) Method of treating or ameliorating metabolic disorders using clec-2
WO2014014819A3 (en) Methods of treating glucose metabolism disorders

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2094663

Country of ref document: EP